NLS Pharmaceutics Shareholders Approve All Agenda Items
Ticker: NCEL · Form: 6-K · Filed: Jan 14, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
Related Tickers: NLS
TL;DR
NLS Pharma shareholders greenlit everything at the Jan 14 meeting.
AI Summary
On January 14, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved. This report is incorporated by reference into several of the company's F-3 registration statements.
Why It Matters
The approval of agenda items at the shareholders' meeting is a necessary step for the company to proceed with its strategic and operational plans.
Risk Assessment
Risk Level: low — The filing reports on routine shareholder meeting outcomes with no new financial or operational risks disclosed.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- January 14, 2025 (date) — Date of shareholders' meeting
FAQ
What was the outcome of the extraordinary shareholders' meeting held by NLS Pharmaceutics Ltd. on January 14, 2025?
All agenda items presented at the extraordinary shareholders' meeting on January 14, 2025, were approved by the shareholders.
Was a quorum present at the NLS Pharmaceutics shareholders' meeting?
Yes, a quorum was present at the extraordinary shareholders' meeting.
Which SEC form is this filing submitted under?
This filing is submitted as a Form 6-K.
What is the principal executive office address for NLS Pharmaceutics Ltd.?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Into which of NLS Pharmaceutics' registration statements is this Form 6-K incorporated by reference?
This Form 6-K is incorporated by reference into NLS Pharmaceutics' Registration Statements on Form F-3 with file numbers 333-282788, 333-262489, 333-268690, and 333-269220.
Filing Stats: 240 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-01-14 16:27:09
Filing Documents
- ea0227681-6k_nlspharma.htm (6-K) — 10KB
- 0001213900-25-003430.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 14, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2